Cancer Research Institute CEO and Director of Scientific Affairs Dr. Jill O’Donnell-Tormey receives inaugural Tara Withington Public Service Award from the Society for Immunotherapy of Cancer.
International neoantigen initiative Tumor Neoantigen Selection Alliance (TESLA) identifies parameters for cancer vaccine or cell therapy advancement
Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.
Cancer Research Institute goes virtual for its Immunotherapy Patient Summit Series,
connecting patients and caregivers with leading experts in cancer immunotherapy.
Cancer Research Institute announces recipients of 2020 philanthropy and science awards to be presented at virtual gala, Innovators in Science and Philanthropy.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.